{"id":7239,"date":"2022-11-03T16:45:03","date_gmt":"2022-11-03T16:45:03","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=7239"},"modified":"2023-02-16T15:53:03","modified_gmt":"2023-02-16T15:53:03","slug":"reinier-van-linschoten-ueg-week-2022-current-health-burden-and-advances-in-the-treatment-of-crohns-disease","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/digestive-disorders\/conference-hub\/reinier-van-linschoten-ueg-week-2022-current-health-burden-and-advances-in-the-treatment-of-crohns-disease\/","title":{"rendered":"Reinier van Linschoten, UEG Week 2022: Current health burden and advances in the treatment of Crohn\u2019s disease"},"content":{"rendered":"

Crohn\u2019s disease is a type of inflammatory bowel disease, where the gastrointestinal tract becomes inflamed, which results in symptoms such as diarrhoea, stomach aches and fatigue. We were delighted to speak with Reinier van Linschoten<\/strong> (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) around the health burden of Crohn\u2019s disease, the disadvantages of current adalimumab dosing regimens in the maintenance of remission and the hot topics and latest research in Crohn\u2019s disease.<\/p>\n

The abstract entitled \u2018CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN\u2019S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL\u2019 (Abstract no: OP106<\/span>) was presented at UEG Week, October 8 \u2013 11, 2022<\/a>.<\/p>\n

Questions<\/strong><\/p>\n

    \n
  1. Could you give us a brief overview of the health burden of Crohn\u2019s disease? (0:22)<\/span><\/li>\n
  2. What are the disadvantages of current dosing regimens in the maintenance of remission in patients with Crohn’s disease? (1:28)<\/span><\/li>\n
  3. What are the hot topics and latest research you are looking forward to exploring in Crohn\u2019s disease? (2:30)<\/span><\/li>\n<\/ol>\n

    Disclosures:<\/strong> Reinier van Linschoten has nothing to disclose in relation to this video interview.<\/p>\n

    Support:<\/strong>\u00a0Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/p>\n

    Filmed as a highlight of UEG Week 2022.<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    Crohn\u2019s disease is a type of inflammatory bowel disease, where the gastrointestinal tract becomes inflamed, which results in symptoms such as diarrhoea, stomach aches and fatigue. We were delighted to speak with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) around the health burden of Crohn\u2019s disease, the disadvantages of […]<\/p>\n","protected":false},"featured_media":7240,"template":"","class_list":["post-7239","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-digestive-disorders","video_categories-ueg-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":9,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7239\/revisions"}],"predecessor-version":[{"id":10742,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7239\/revisions\/10742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/7240"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=7239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}